Ilevro Shortage: What Providers and Prescribers Need to Know in 2026

As an ophthalmologist or other prescriber routinely managing post-cataract care, you've likely had patients report difficulty filling their Ilevro prescription. This guide provides current availability data, clinical context, therapeutic alternatives, and practical patient management strategies for 2026.

Current Ilevro Availability Status

Ilevro (nepafenac ophthalmic suspension 0.3%) is not on the FDA's drug shortage list as of 2026. Harrow, which acquired the Ilevro brand from Alcon/Novartis, states that the product is widely available with strong formulary coverage across commercial insurance plans and Medicare Part D (Tier 3). Harrow's November 2024 Access and Affordability Program — including a GoodRx partnership — was designed in part to address patient cost barriers that drive non-fill rates.

That said, pharmacies in lower-volume areas or outside major ophthalmology corridors may not maintain proactive inventory. Patients present at your office or surgery center reporting they couldn't find Ilevro at their neighborhood pharmacy — even when no systemic shortage exists.

Why Patients Report Difficulty Finding Ilevro

The key structural factors contributing to patient fill challenges for Ilevro:

No generic equivalent: As of 2026, the FDA has not approved a generic version of nepafenac 0.3%. All supply originates from a single manufacturer, creating concentration risk at the retail level.

Specialty stocking decisions: Most retail pharmacies stock drugs based on local prescription volume. Ilevro, as a surgical adjunct with episodic demand, may not meet automatic reorder thresholds at general community pharmacies.

High cash-pay price: Retail prices of $380–$482 per bottle create access barriers for patients not aware of the Harrow Connects Savings Program or GoodRx discounts, which can reduce cost to as low as $59–$149.

Insurance prior authorization delays: While 84% of commercial plans cover Ilevro, Tier 3 placement on Medicare Part D may result in prior authorization requirements that delay fill for older patients — a key demographic for cataract surgery.

Clinical Context: Why Timely NSAID Access Matters

The Ilevro dosing protocol begins 1 day pre-operatively, with an additional drop 30-120 minutes before surgery. Post-operative dosing continues for 14 days. This pre-treatment window is clinically meaningful: pre-loading cyclooxygenase inhibition suppresses prostaglandin release at the time of surgical trauma, reducing intraoperative miosis and the subsequent inflammatory cascade.

Failure to initiate pre-operative dosing — or delaying post-operative NSAID coverage — increases patient risk for pseudophakic cystoid macular edema (PCME), the most common cause of reduced visual acuity after otherwise uncomplicated cataract surgery. Patients at elevated PCME risk (diabetics, history of uveitis, vitreoretinal disease, membrane peeling) require particular vigilance around NSAID continuity.

Therapeutic Alternatives: Clinical Comparison

When Ilevro is unavailable, the following substitutions are appropriate for most patients:

Bromfenac (generic 0.07%/0.09%): Once or twice daily dosing; generic available and widely stocked at $80–$200/bottle. Has demonstrated efficacy comparable to nepafenac in multiple RCTs. Generally the first-choice substitution.

Nevanac (nepafenac 0.1%): Same active molecule, lower concentration, TID dosing. No generic; similar cost to Ilevro. May be available when Ilevro is not at certain pharmacies.

Ketorolac 0.5% (generic): QID dosing; most affordable option ($15–$50). Widely stocked. Consider for cost-sensitive patients or where supply chain issues are broader. Acuvail (preservative-free 0.45%) offers BID dosing and may be preferred in patients with ocular surface disease.

Diclofenac 0.1% (generic): QID dosing; $20–$60 as a generic. Well-established for PCME prevention. Good option when cost is the primary concern.

Practice Management: Strategies to Reduce Fill Failures

To minimize Ilevro fill delays at your practice, consider these approaches:

Partner with a preferred pharmacy. Establish a relationship with one or two pharmacies near your surgical center that maintain reliable Ilevro inventory. Share your weekly case volume so they can plan stocking accordingly.

Pre-authorize with insurance. For Medicare patients, pre-empt prior authorization delays by submitting PA requests at the time of surgical scheduling, not the day of surgery.

Educate patients on savings programs. At the time of prescription, provide patients information about the Harrow Connects Savings Program (harrowconnects.com) and GoodRx pricing. Unaware patients often abandon fills based on sticker shock.

Recommend medfinder to patients. For patients who've already encountered fill difficulties, medfinder calls pharmacies near them to identify which ones have Ilevro in stock — a practical step that saves patients significant time.

Maintain sample stock. A small inventory of Ilevro samples from your Harrow representative can bridge the gap when patients encounter unexpected fill delays the day before surgery.

Looking Ahead: Ilevro Supply Risk Assessment

Ilevro's supply risk profile is moderate-low compared to generic sterile injectables and stimulant medications that dominate shortage headlines. As a brand-name ophthalmic, it benefits from higher manufacturing margins and a committed commercial distributor. However, the single-source nature of its supply (no generic equivalent) means any manufacturing or distribution disruption at Harrow would have an outsized impact. Staying alert to ASHP shortage alerts and FDA notifications remains advisable.

For specific strategies on helping your patients locate Ilevro, see our companion guide: How to Help Your Patients Find Ilevro in Stock: A Provider's Guide.